Development of VIII inhibitors beyond 50 exposure days to rFVIII during prophylactic emicizumab therapy
Haemophilia · 2023
DOI: 10.1111/hae.14854 ↗Kurz gefasst
Leserbrief in der Zeitschrift Haemophilia, 2023. Verfasst von Yuichi Mitani und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology/Oncology, Saitama Children's Medical Center, Saitama, Japan. Hauptthemen laut MEDLINE: Antibodies, Bispecific, Hemophilia A. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 10 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Hematology/Oncology, Saitama Children's Medical Center, Saitama, Japan.
- Department of Orthopedic Surgery, Saitama Children's Medical Center, Saitama, Japan.
- Department of Radiology, Saitama Children's Medical Center, Saitama, Japan.
ORCID-Profile: Yuichi Mitani
Zitieren
APA
Mitani, Y., Honda, M., Mizushima, Y., Mori, M., Fukuoka, K., Oshima, K., Arakawa, Y., Taira, K., Tanami, Y., & Koh, K. (2023). Development of VIII inhibitors beyond 50 exposure days to rFVIII during prophylactic emicizumab therapy. Haemophilia. https://doi.org/10.1111/hae.14854
Vancouver
Mitani Y, Honda M, Mizushima Y, Mori M, Fukuoka K, Oshima K, et al. Development of VIII inhibitors beyond 50 exposure days to rFVIII during prophylactic emicizumab therapy. Haemophilia. 2023. doi:10.1111/hae.14854
BibTeX
@article{Mitani2023,
author = {Mitani, Yuichi and Honda, Mamoru and Mizushima, Yoshitaka and Mori, Makiko and Fukuoka, Kohei and Oshima, Koichi and Arakawa, Yuki and Taira, Katsuaki and Tanami, Yutaka and Koh, Katsuyoshi},
title = {Development of VIII inhibitors beyond 50 exposure days to rFVIII during prophylactic emicizumab therapy},
journal = {Haemophilia},
year = {2023},
doi = {10.1111/hae.14854}
}
EUVIMED